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AbstrAct
Objective To characterise the long-term prognosis of 
patients with stable coronary artery heart disease by 
means of ‘standard predictors’ defined as demographic, 
clinical and biochemical quantities routinely available in 
general practices and ascertained at an interview not 
prompted by renewed cardiac complaints.
Methods This is an observational study based on data from 
2199 Copenhagen placebo patients from the ‘clarithromycin 
for patients with stable coronary heart disease’ trial of 
patients with stable coronary heart disease. In the trial, we 
compared the effects of 14 days of clarithromycin treatment 
versus placebo. The predictors were based on the interview 
forms and blood samples collected at entry, along with 
demographic information from hospital files.
We studied ‘standard predictors’ of a composite outcome 
(myocardial infarction, unstable angina, cerebrovascular 
disease or all-cause death) and of all-cause death. Using Cox 
regression, we compared predictions of status at 3, 6 and 9 
years without and with the use of ‘standard predictors’ and 
used receiver operating characteristic statistic.
Results Few ‘standard predictors’ were associated 
(p<0.01) with the composite outcome or with all-cause 
death. When no ‘standard predictors’ were included, 
63.2% of the model-based predictions of the composite 
outcome and 79.9% of death predictions were correct. 
Including all ‘standard predictors’ in the model increased 
the figures to 68.4% and 83.4%, respectively. C indices 
were low, except when all-cause death was assessed as a 
single outcome where C was 0.79.
Conclusion ‘Standard predictors’ routinely available 
in general practices contribute only modestly to risk 
assessment in consecutively sampled patients with 
stable coronary heart disease as ascertained at a contact 
not prompted by renewed cardiac complaints. Novel 
biomarkers may improve the assessment.
Trial registration number NCT00121550.
InTROduCTIOn
It would be of great practical value if the 
long-term prognosis of patients with stable 
coronary heart disease could be assessed by 
the general practitioner at a random time 
during the patient’s disease course, that is, 
when the visit at the general practitioner is 
not prompted by acute symptoms or made 
during recovery from a major cardiovascular 
event. To be practically useful, the assessment 
should be based on information routinely 
available to the general practitioner. The term 
‘stable coronary heart disease’ calls for a defi-
nition that is readily applied in general prac-
tice. In the ‘clarithromycin for patients with 
stable coronary heart disease’ (CLARICOR) 
Key questions
What is already known about this subject?
 ► Patients with stable coronary artery disease are at 
an increased risk of death or non-fatal cardiovas-
cular incidents.
What does this study add?
 ► New knowledge regarding the long-term impact 
of routinely measured, demographic, clinical and 
biochemical factors for the prediction of non-fatal 
cardiovascular incidents and all-cause death in 
patients with stable coronary heart disease ascer-
tained at baseline review not prompted by renewed 
cardiac complaints.
 ► Routinely measured, demographic, clinical and bio-
chemical factors do show an expected association 
with long-term course, but the prognostic impact is 
weak. For useable prognostic differentiation, stron-
ger clinical markers are needed.
How might this impact on clinical practice?
 ► High-risk patients with stable coronary heart dis-
ease presenting in a general practice with non-car-
diac complaints may be identified using ‘standard 
predictors’ and advanced biomarkers and referred 
to further examinations by specialist cardiologists.
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trial,1 2 we have developed the operational definition 
described below, covering a common and important class 
of patients.
Our present objective, therefore, is to use the data 
from the CLARICOR trial to identify relevant prognostic 
quantities, readily available during clinical routine work, 
when a patient with stable coronary heart disease is seen 
by the practising physician for reasons other than renewed 
cardiac complaints. Such quantities may prove useful as a 
background for closer investigation of selected patients. 
The present analysis also serves as a background for a 
search for additional prognostic covariates which may 
be available in the biobank of the CLARICOR trial. A 
detailed account of methodology and statistical analysis 
was published before the analysis commenced.3
MaTeRIals
Patients
In the CLARICOR trial, 13 702 patients aged 18–85 years 
who had a discharge diagnosis of myocardial infarction 
or angina pectoris during 1993–1999 and were alive in 
August 1999 were invited by letter for a 14-day trial of 
clarithromycin versus placebo.1 2 Of the 13 702 patients, 
6116 accepted the invitation. Of these, 177 refused to 
participate and 1567 were excluded while 4372 were 
randomised.
Baseline data were obtained from the hospital files and 
patient interviews at six cardiology clinics covering the 
Copenhagen area. Initial follow-up lasted for 2.6 years, 
during which outcomes were collected through hospital 
and death registries and assessed by an adjudication 
committee.2 Corresponding register data later showed to 
produce similar results.4 5 The adjudicated outcomes were 
therefore replaced and augmented by register outcomes 
to cover 10 years of follow-up. Biochemical data were 
obtained from analysis of serum from the CLARICOR 
biobank collected at randomisation and stored at −80°C.
The patients excluded from the trial were those who 
fulfilled the following conditions: (1) suffered from acute 
myocardial infarction or unstable angina pectoris within 
the previous 3 months; (2) had percutaneous translu-
minal coronary angioplasty and coronary bypass surgery 
within the previous 6 months; (3) with impaired renal, 
or (4) hepatic dysfunction, (5) congestive heart failure 
(New York Heart Association (NYHA) IV classification 
of heart failure), or (6) active malignancy; (7) without 
capacity to manage own affairs; and (8) without breast 
feeding or possible pregnancy.
The main results of the CLARICOR trial were that clar-
ithromycin increased the risk of cardiovascular as well 
as all-cause death.1 6–8 Therefore, we here focus on the 
placebo group.
Predictors
Data material collected from the 2199 placebo patients 
was covering the period until 31 December 2009, that is, 
10 years (±3 months), and was obtained by use of public 
registers with almost 100% coverage,4 5 as explained in 
the Outcomes section and in refs 4–6.
Demographic and anamnestic data
Enrolment interviews provided smoking status, current 
medication and known hypertension or diabetes, while 
information concerning sex, age and history of myocar-
dial infarction or unstable angina pectoris was obtained 
from the local hospital files.
Biochemical measurements on plasma collected at entry
Biochemical measurements on plasma collected at entry 
included lipoproteins,9 high-sensitivity C-reactive protein 
(hs-CRP/mg/L)10 and glomerular filtration rate (GFR/
mL/min) using creatinine.11 Along with variables already 
mentioned, these quantities are those collectively referred 
to as ‘standard predictors’ and specified in table 1.
Outcomes
We assessed the time from randomisation until the first 
occurrence of one of the following events: acute myocar-
dial infarction, unstable angina pectoris, cerebrovascular 
disease and all-cause death (the composite outcome) and 
the time from randomisation to all-cause death. The algo-
rithm used to get from the International Statistical Clas-
sification of Diseases used in the national registries12 13 
to the events of the composite outcome is described in 
refs 4 5.
MeTHOds
statistical analysis
We used the Cox proportional hazards model supple-
mented by Breslow estimation of the baseline hazard and 
using SAS V.9.4 in agreement with our peer-reviewed, 
published statistical analysis plan.3 The model assump-
tions were tested using Bonferroni adjusted p values.3 14
There are virtually no missing data from entry infor-
mation in the CLARICOR trial3 but 9.4% of the patients 
had one or more laboratory test values missing. We used 
Little’s test to decide whether to use multiple imputation 
or a complete case analysis.15
All analyses that included covariates were stratified by 
centre. For each covariate, we examined if it interacted 
significantly with sex (using a Bonferroni adjustment).
Inference analyses
If an HR showed a deviation from 1.00 such that p<0.01, 
we classified the variable as a prognostic predictor, given 
the outcome analysed and the other covariates included 
in the analysis. We identified the prognostic predictors 
among the ‘standard predictors’ for each of the two 
outcomes, the predictor being tested when used alone in 
a Cox regression analysis (except for age, see below) and 
when used in combination with the remaining ‘standard 
predictors’.3
assessing the prognostic utility of the ‘standard predictors’
We used the Cox-Breslow method to estimate the survival 
curve of the outcome of each patient using all available 
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Table 1 The distributions of standard predictors in the placebo group and in the group of patients who received 
clarithromycin
Standard predictors Placebo patients (n=2199) Clarithromycin patients (n=2172)
Demographics and history
Sex (male), n (%) 1518 (69.0) 1514 (69.7)
Age/year, mean (SD) 65.2 (10.4) 65.4 (10.3)
Smoking status (smoking, ex-smoker, never smoked), n 
(%)
Smokers, 753 (34.2)
Ex-smokers, 1011 (46.0)
Never smoked, 435 (34.2)
Smokers, 819 (37.6)
Ex-smokers, 982 (45.2)
Never smoked, 371 (17.1)
Hypertension, n (%) 883 (40.2) 878 (40.4)
Diabetes, n (%) 337 (15.3) 341 (15.7)
Previous AMI, n (%) 1494 (67.9) 1470 (67.7)
Current medication
Aspirin, n (%) 1937 (88.1) 1902 (87.6)
Beta-blocker, n (%) 681 (31.0) 653 (30.1)
Calcium antagonist, n (%) 772 (35.1) 755 (34.8)
ACE inhibitor, n (%) 577 (26.3) 604 (27.8)
Long-lasting nitrate, n (%) 457 (20.8) 453 (20.9)
Diuretics, n (%) 773 (35.2) 762 (35.1)
Digoxin, n (%) 126 (5.7) 154 (7.1)
Statins, n (%) 904 (41.1) 896 (41.3)
Antiarrhythmic drugs, n (%) 51 (2.3) 55 (2.5)
Biochemical predictors
Log (CRP/mg/L) mean (SD), n* 1.03 (1.12) 2159 1.07 (1.15) 2128
ApoA1/mg/dL mean (SD), n 1.70 (0.34) 2076 1.70 (0.36) 2041
Log (ApoB/mg/dL) mean (SD), n 0.16 (0.27) 2075 0.15 (0.27) 2040
Chol-HDL/mmol/L mean (SD), n 1.02 (0.32) 2074 1.02 (0.32) 2039
Chol-LDL/mmol/L mean (SD), n 2.56 (0.72) 2079 2.55 (0.73) 2044
Log(cholesterol/mmol/L) mean (SD), n 1.73 (0.20) 2075 1.72 (0.20) 2039
Log(triglyceride/mmol/L) mean (SD), n 0.73 (0.53) 2078 0.71 (0.52) 2040
Glomerular filtration rate (GFR/mL/min) mean (SD), n 71.8 (19.2) 2079 72.1 (19.2) 2044
*The value of n varies because the laboratory tests have missing values.
AMI, acute myocardial infarction; Chol, cholesterol; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Log, 
natural logarithm.
information. From the curve, we read off the probabili-
ties that the patient will be event free at time T=3, 6 and 
9 years. If the probability is larger than or equal to 0.5, we 
make the favourable (F) prediction that the patient is still 
event free at time T; otherwise, we make the unfavour-
able (un-F) prediction that the patient experiences an 
event before T. The truth values of the predictions were 
determined by comparison with the observed records. 
To assess the role of the covariates in these predictions 
we repeated the procedure without introducing any 
covariates (the Cox output then reduces to a Kaplan-
Meier curve). Here we used methods that do not allow 
time-dependent covariates, so in this case stratification 
on age was used (cutting at 60 and 75 years) and age was 
excluded as a covariate.16
We also analysed data using a parametric, accelerated 
failure time model. For the underlying time-to-event 
distribution type of the accelerated failure time model, 
we considered several choices using q-q graphs to assess 
the fit14 (p 100). The generalised gamma model gave a 
perfect fit for the composite outcome and a reasonable 
fit for all-cause mortality.
Using the events observed during the first 9 years of 
follow-up, the prognostic differentiation was character-
ised by receiver operating characteristics (ROC) and 
‘predictive impact’ diagrams.17–19 The hazard estimation 
is based on the full 10-year follow-up of 1998 patients 
with complete covariate data but the ROC analysis is 
limited to what happened to them within the 9-year 
window.
The calculations involve a prognostic rule being 
applied to the same data sample from which it was 
derived. But model fit is assessable (see the ROC 
diagram).
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Figure 1 (A) Kaplan-Meier estimate (with 95% CI) of composite outcome including acute myocardial infarction, unstable 
angina pectoris, cerebrovascular disease, and all-cause death. Figures below the curve are biannual number at risk in the 
placebo group of the CLARICOR trial. (B) Kaplan-Meier estimate (with 95% CI) of the outcome all-cause death. Figures below 
the curve are biannual number at risk in the placebo group of the CLARICOR trial.
ResulTs
As Little’s test15 had p=0.93, we used complete case anal-
yses in the following.
Table 1 presents an overview of the covariates expected 
to be available from patients with stable cardiovascular 
disease during clinical routine work (‘standard predic-
tors’). We have shown the corresponding data of the 
clarithromycin group to illustrate that the randomisa-
tion was successful. It appears that the results are consis-
tent across the placebo group and the clarithromycin 
group. Figure 1 presents the Kaplan-Meier curves for 
the composite outcome (figure 1A) and all-cause death 
(figure 1B). At 2 years, 1826 (83.0%) had not yet suffered 
a composite outcome and 2073 (94.3%) were still alive. 
At 6 years, 1261 (57.3%) had not yet suffered a composite 
outcome and 1758 (79.9%) were still alive. At 9 years, the 
numbers are 969 (44.9%) and 1487 (67.6%), respectively. 
In the following we shall describe the differentiation of 
these risks offered by the covariates presented in table 1.
Testing the ‘standard predictors’
As the proportional hazards assumption was violated for 
age we included an interaction between age at entry and 
time (since randomisation) in the inference analyses.
Table 2 shows the HR of each of the ‘standard predic-
tors’ when used alone in a Cox analysis (table 2, columns 
2–4) and when used in combination with the rest of 
the ‘standard predictors’ for the composite outcome 
(table 2, columns 5–7). The main effect of age is only 
significant when no adjustment by the ‘standard predic-
tors’ is used. By contrast, the interaction between age and 
time is significant with and without adjustment. Smoking 
habits, diabetes, most of the medication indicators, 
log (hs-CRP) and reduced GFR predict the risk of the 
composite outcome when used alone (the threshold of 
p<0.01). In the analysis that included all the ‘standard 
predictors’, smoking habits, diabetes, long-lasting nitrate 
medication, digoxin medication and GFR provided prog-
nostic information.
Table 3, whose structure is the same as that of table 2, 
shows the results for all-cause death. When each predictor 
is assessed alone, the results are much like those for the 
composite outcome. Smoking habits, diabetes, most of 
the medication indicators, log (hs-CRP) and reduced 
GFR predict the risk of all-cause death when used alone 
(p<0.01). When all ‘standard predictors’ are included, 
male sex now becomes also significantly unfavourable 
in association with smoking habits, diuretic medication, 
digoxin medication, log (hs-CRP) and reduced glomer-
ular filtration rate. The biochemical lipid quantities were 
not prognostic.
For neither outcome did any standard predictor 
interact significantly with sex.
Prognostic impact of the ‘standard predictors’
Table 4 (columns 2–3) shows the types, numbers and 
percentages of correct predictions obtained when 
we used the Cox model and the composite outcome 
without covariates included (column 2) and when the 
‘standard predictors’ (and age strata, see the Methods 
section) were included. The percentages are correct 
predictions over total number of predictions made 
(three per patient unless dropout, see footnote §, 
table 4). Without covariates included in the model, 
63.2% of the predictions were correct. With ‘standard 
predictors’ included, 68.4% became correct, increasing 
the number of correct predictions by only 5.2%, and 
leaving 31.6% in error.
For the all-cause death outcome (see table 4, lower half, 
left side), the corresponding percentages were 79.9%, 
83.4%, 3.5% and 16.6%, respectively. So, it appears that 
the contributions of the individual’s own routine data 
(the ‘standard predictors’) to the predictions are rather 
modest.
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Table 2 Composite outcome including acute myocardial infarction, unstable angina pectoris, cerebrovascular disease and 
all-cause death. HRs of standard predictors when used alone and when used in combination with the rest of the standard 
predictors
Standard predictors
Single predictor examined in the model 
(stratified by centre)
All standard predictors in the model 
(stratified by centre)
HR 95% CI of HR P values HR 95% CI of HR P values
Demographics and history
Sex (male=1) 1.004 0.889 to 1.134 0.95 1.150 1.005 to 1.315 0.042
Age/year 1.024 1.013 to 1.034 <0.0001 1.013 1.001 to 1.025 0.030
Age∙time*/year∙year 1.00374 1.002 to 1.006 0.0004 1.004 1.002 to 1.006 <0.0001
Smoking status (ex-smoker compared with 
never smoking)
1.203 1.026 to 1.410 0.0062 1.210 1.025 to 1.428 <0.0001
Smoking status (smoking compared with never 
smoking)
1.309 1.110 to 1.545 1.547 1.300 to 1.842
Hypertension, Y/N 1.105 0.985 to 1.239 0.090 0.991 0.870 to 1.129 0.89
Diabetes, Y/N 1.318 1.133 to 1.533 0.0003 1.261 1.076 to 1.480 0.0043
Previous AMI, Y/N 1.169 1.033 to 1.324 0.014 1.151 1.012 to 1.308 0.032
Current medication
Aspirin, Y/N 0.978 0.820 to 1.165 0.80 1.021 0.852 to 1.225 0.82
Beta-blocker, Y/N 1.010 0.893 to 1.141 0.88 1.013 0.888 to 1.155 0.85
Calcium antagonist, Y/N 1.232 1.095 to 1.385 0.0005 1.121 0.982 to 1.279 0.090
ACE inhibitor, Y/N 1.246 1.099 to 1.412 0.0006 1.054 0.916 to 1.213 0.46
Long-lasting nitrate, Y/N 1.738 1.527 to 1.978 <0.0001 1.348 1.172 to 1.551 <0.0001
Diuretics, Y/N 1.613 1.437 to 1.810 <0.0001 1.180 1.030 to 1.352 0.017
Digoxin, Y/N 2.212 1.805 to 2.711 <0.0001 1.576 1.269 to 1.957 <0.0001
Statins, Y/N 0.746 0.663 to 0.839 <0.0001 0.883 0.769 to 1.014 0.077
Antiarrhythmic drugs, Y/N 1.119 0.763 to 1.642 0.56 0.924 0.627 to 1.362 0.69
Biochemical predictors
Log(CRP/mg/L) 1.171 1.113 to 1.232 <0.0001 1.070 1.014 to 1.480 0.014
ApoA1/mg/dL 0.905 0.764 to 1.072 0.25 0.707 0.516 to 0.969 0.031
Log(ApoB/mg/dL) 1.165 0.938 to 1.447 0.17 0.826 0.413 to 1.651 0.59
Chol-HDL/mmol/L 0.954 0.794 to 1.147 0.62 1.104 0.714 to 1.708 0.66
Chol-LDL/mmol/L 1.027 0.948 to 1.112 0.52 0.912 0.751 to1.107 0.35
Log (cholesterol/mmol/L) 1.247 0.940 to 1.654 0.13 1.786 0.577 to 5.525 0.31
Log (triglycerides/mmol/L) 1.024 0.919 to 1.141 0.67 1.030 0.878 to 1.208 0.72
Glomerular filtration rate (GFR/mL/min) 0.985 0.982 to 0.988 <0.0001 0.995 0.991 to 0.999 0.0084
*Time is years since randomisation.
AMI, acute myocardial infarction; Chol, cholesterol; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; N, 
hypertension is not present; Y, hypertension is present.
Table 4 (columns 4 and 5) shows the corresponding 
results obtained when we used the accelerated failure 
time model. These results are very similar to those 
obtained using the Cox model.
Table 5 shows the C indices for the composite outcome 
and its components, describing concordance as to 
whether patients were to experience the event in ques-
tion (within the 9-year window). The underlying ROC 
curve is given in figure 2Afor all-cause death. The empir-
ical curve (dashed) shows that the 644 deaths and 1354 
survivals closely fit the predicted pattern (smooth curve).
Figure 2Bholds a ‘predictive impact’ graph, designed 
to compare the predictive power of rival prognostic rules. 
The diagram estimates the benefit that might accrue 
by treating high-risk patients if a completely effective 
preventive intervention existed. The patients are ordered 
according to assigned risk (just as in the ROC). As a func-
tion of the percentage imagined to be selected for treat-
ment (abscissa), the ordinate shows how many deaths 
(dashed) and life-years (fat curve) would be saved. Within 
the 9-year window, the 644 deaths will cause 2703 years to 
be lost without treatment. From the graph it may be read 
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Table 3 All-cause death. HRs of standard predictors when used alone and when used in combination with the rest of the 
standard predictors
Standard predictors
Single predictor examined in the model 
(stratified by centre)
All ‘standard predictors’ in the model 
(stratified by centre)
HR 95% CI of HR P values HR 95% CI of HR P values
Demographics and history
Sex (male=1) 0.970 0.831 to 1.132 0.70 1.329 1.119 to 1.578 0.0012
Age/year 1.065 1.046 to 1.084 <0.0001 1.047 1.027 to 1.068 <0.0001
Age∙time*/year∙year 1.00305 1.000056 to 1.0061 0.045 1.004 1.001 to 1.007 0.011
Smoking status (ex-smoker compared with 
never smoking)
1.366 1.109 to 1.683 0.0071 1.436 1.155 to 1.786 <0.0001
Smoking status (smoking compared with never 
smoking)
1.379 1.109 to 1.714 2.135 1.692 to 2.693
Hypertension, Y/N 1.117 0.965 to 1.293 0.14 1.001 0.848 to 1.181 0.99
Diabetes, Y/N 1.456 1.211 to 1.751 <0.0001 1.410 1.161 to 1.713 0.0005
Previous AMI, Y/N 1.166 0.995 to 1.368 0.058 1.161 0.985 to 1.369 0.075
Current medication
Aspirin, Y/N 0.854 0.689 to 1.059 0.15 0.898 0.718 to 1.124 0.35
Beta-blocker, Y/N 0.926 0.790 to 1.084 0.34 0.916 0.773 to 1.085 0.31
Calcium antagonist, Y/N 1.193 1.028 to 1.385 0.020 0.999 0.845 to 1.181 0.99
ACE inhibitor, Y/N 1.349 1.153 to 1.579 0.0002 1.056 0.886 to 1.258 0.54
Long-lasting nitrate, Y/N 1.776 1.513 to 2.084 <0.0001 1.178 0.991 to 1.400 0.063
Diuretics, Y/N 2.183 1.889 to 2.524 <0.0001 1.432 1.210 to 1.694 <0.0001
Digoxin, Y/N 3.008 2.388 to 3.790 <0.0001 1.826 1.428 to 2.334 <0.0001
Statins, Y/N 0.597 0.511 to 0.697 <0.0001 0.812 0.675 to 0.976 0.027
Antiarrhytmic drugs, Y/N 1.113 0.677 to 1.830 0.67 0.798 0.482 to 1.320 0.38
Biochemical predictors
Log(CRP/mg/L) 1.283 1.202 to 1.370 <0.0001 1.147 1.070 to 1.230 0.0001
ApoA1/mg/dL 1.089 0.878 to 1.351 0.44 0.928 0.615 to 1.401 0.72
Log(ApoB/mg/dL) 0.923 0.704 to 1.210 0.56 0.483 0.202 to 1.156 0.10
Chol-HDL/mmol/L 1.192 0.947 to 1.501 0.13 0.884 0.503 to 1.551 0.67
Chol-LDL/mmol/L 0.958 0.865 to 1.060 0.41 0.982 0.772 to 1.250 0.88
Log (cholesterol/mmol/L) 1.169 0.819 to 1.668 0.39 1.895 0.455 to 7.899 0.38
Log (triglycerides/mmol/L) 0.868 0.755 to 0.997 0.045 0.882 0.716 to 1.086 0.24
Glomerular filtration rate (GFR/mL/min) 0.972 0.969 to 0.976 <0.0001 0.990 0.985 to 0.994 <0.0001
*Time is years since randomisation.
AMI, acute myocardial infarction; Chol, cholesterol; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; N, hypertension is not present; Y, hypertension is present.
that if 10% of the patients were to be treated with a 100% 
effective intervention, 29% of the total loss of years may 
be saved.
dIsCussIOn
In this study, we assessed the predictive value of ‘standard 
predictors’ routinely available for a general practitioner 
when he/she meets a patient with stable coronary heart 
disease whose visit is not prompted by renewed cardiac 
complaints. When no ‘standard predictors’ were included 
in the prediction, 63.2% of the model-based predictions 
of the composite outcome and 79.9% of all-cause death 
predictions were correct. Including all ‘standard predic-
tors’ in the model increased the figures to 68.4% and 
83.4%, respectively.
We have not been able to identify a study where death 
of all causes and cardiovascular insults have been assessed 
in patients with (1) stable coronary heart disease of a type 
like the above described, (2) with a 10-year follow-up, and 
(3) where the clinical examination was not prompted 
by renewed cardiovascular complaints. Taken together, 
most of the studies we identified were either analysing 
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Table 4 The types and numbers of correct predictions obtained when the Cox proportional hazards model was used and 
when the accelerated failure model (using generalised gamma distribution) was used. For comparison, the results without 
covariates included are shown
Type of predictions*
Statistical model used
Cox proportional hazards model†
Accelerated failure model (using 
generalised gamma distribution)
No covariates
Covariates 
included No covariates Covariates included
Composite outcome‡ 
True favourable predictions, n (%) (out of a total of 
5970 predictions made)§
2658 (44.5) 2910 (48.7) 2658 (44.5) 2918 (48.9)
True unfavourable predictions, n (%) (out of a total of 
5970 predictions made)
1115 (18.7) 1174 (19.7) 1115 (18.7) 1197 (20.0)
Total number of true predictions, n (%) (out of a total 
of 5970 predictions made)
3773 (63.2)§ 4084 (68.4) 3773 (63.2) 4115 (68.9)
All-cause death
True favourable predictios, n(%) (out of a total of 5970 
predictions made)
4768 (79.9) 4585 (76.8) 4768 (79.9) 4563 (76.4)
True unfavourable predictions, n (%) (out of a total of 
5970 predictions made)
0 (0)¶ 392 (6.57) 0 (0) 401 (6.72)
Total number of true predictions, n (%) (out of a total 
of 5970 predictions made)
4768 (79.9) 4977 (83.4) 4768 (79.9) 4964 (83.1)
*For each patient at time (T) equal to 3, 6 and 9 years and using the patient’s individual survival curve the predicted outcome (patient ‘alive 
at T’ (favourable outcome) compared with patient ‘not alive at T’ (unfavourable outcome)) was read off the survival curve and the results 
compared with the observed outcome. When no covariates were included in the model, the Kaplan-Meier survival curve was used to 
calculate the predictions.
†Time-dependent covariates were not allowed in the SAS V.9.4 program used. To allow for the fact that age violated the proportional hazard 
assumption we stratified by age categories (see text) in addition to centre and excluded age from the covariates.21
‡Comprising acute myocardial infarction, unstable angina pectoris, cerebrovascular disease and all-cause death.
§n is the number of true predictions made. The per cent is n over the total number of predictions made. 5970 predictions are made, namely 
1998 patients with complete covariates times three time points (at 3, 6 and 9 years) minus 24 predictions not checkable due to patients lost 
to registries. Of these predictions, a total of 3773 were true which amounts to 3773/5970=63.2%.
¶As total mortality is <50%, all predictions are automatically favourable (and 79.9% of them pertain to a so far survivor).
small study samples, for example,20 were developed in 
patients with acute coronary syndromes,21 or had short 
follow-up.22
In many respects, our patients are like those of the 
Prospective Observational Longitudinal Registry of 
Patients with Stable Coronary Heart Disease (CLARIFY) 
study23 which enrolled 20 291 patients of whom 20% 
had anginal symptoms corresponding to the 20% of 
our patients who took long-lasting nitrates. Patients with 
hospital admission for cardiovascular reasons (including 
revasculariation) in the past 3 months before enrolment 
or conditions interfering with life expectancy such as 
cancer and NYHA class 4 were excluded. So, in these 
respects, the CLARIFY patients are like our patients. 
However, the CLARIFY patients had been observed with 
a median of 24.1 months and enrolment took place 10 
years later than in the CLARICOR trial. A total of 469 
cardiovascular deaths or myocardial infarctions occurred 
in these patients (2.3%).23 By contrast, in our cohort 
the corresponding numbers found during the first 2 
years of observation were 170 cardiovascular deaths and 
7.7%, respectively, probably reflecting improved quality 
of treatment and more frequent statin treatment in the 
CLARIFY patients (84% vs only 41% in the CLARICOR 
patients).
Many of our ‘standard predictors’ showed that they 
contained statistically significant prognostic informa-
tion. However, few of the ‘standard predictors’ contrib-
uted statistically significant prognostic information 
when all predictors were tested simultaneously. More-
over, the ‘standard predictors’ offered little prognostic 
discrimination.
Methodology
Regarding our methodology, the performance statistics 
reported here are minimal, but they suffice to show that 
the results are meagre, leaving room for improvement 
with advanced biomarkers.3 Prediction at 3, 6 and 9 years 
covers the follow-up as well as would a sophisticated inte-
gral over continuous time. Using 0.50 as a probability 
threshold is again a least arbitrary choice (the relative 
impact of false and true predictions being unknown), 
as is the ROC principle. Adding realism to the naked 
construct of a ‘completely effective preventive interven-
tion’ (figure 2B) would again be subject to criticism in 
the absence of alternatives, with solid empirical backing.
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Table 5 Receiver operating characteristic (ROC) areas (C 
indices) of placebo patients with complete records (n=1998). 
Nine-year risks assigned by the Cox analysis using all 
standard predictors
Outcome
Ordinary ROC 
area (event Yes 
compared with No, 
regardless of time)
Dynamic C 
index*
Acute myocardial 
infarction (AMI)
0.643 0.651
Unstable angina pectoris 
(UAP)
0.637 0.616
Cerebrovascular disease 
(CVD)
0.606 0.680
Cardiovascular death 
(non-cardiovascular death)
0.761 (0.736) 0.730 (0.728)
All-cause death 0.792 0.737
Composite outcome† 0.711 0.640
*When a patient had no event of the kind concerned within the 
9-year window, we define: toe (time of event) = + ∞. Then, C is 
the frequency of concordant risks (equal risk weighs 1/2) among 
patient pairs whose toe data allow us to decide who died first: 
C=freq {concordant risks (or equal risk, 0.5) | sign of toe difference 
known from data}.
†Consists of acute myocardial infarction, unstable angina pectoris, 
cerebrovascular disease and all-cause death.
Figure 2 (A) ROC diagram (death vs survival at 9 year data). (B) Predicted imapct curves. ROC, receiver operating 
characteristic.
strengths
The strengths of the CLARICOR trial are the consider-
able size of the patient population, the long duration 
of follow-up, few losses to follow-up (0.5%), the ethnic 
homogeneity of the patient population, rarity of missing 
values, with focus on an operationally defined, homoge-
neous and relevant patient category. The design implies 
that the patients are sampled at random, presumably 
uneventful, time points during their stable state (as 
defined by the CLARICOR trial). Furthermore, the large 
biobank formed during the trial allows an extensive 
search for new advanced biomarkers to be made.
limitations
Among those 7586 patients who declined our invitation 
to visit a cardiology centre, many must have been eligible 
for the CLARICOR trial, and we do not know how they 
looked and fared. With a response rate of about 50%, the 
cohort could represent a prognostic elite if responders 
were mostly mobile and health-conscious patients. So, 
selection bias cannot be excluded.
Furthermore, the patients recruited for the CLARICOR 
trial were diagnosed with coronary heart disease about 
20 years ago. Because of the tremendous developments 
in treatment and rehabilitation, there has been a very 
significant and graded increase in prognosis of such 
patients,24 as shown in national data.25 Given these uncer-
tainties, prognostic findings in the CLARICOR cohort 
should not directly be applied to present-day patient 
materials. However, the overall picture regarding the 
relative predictive effect of ‘standard predictors’ and 
advanced biomarkers should provide relevant and valu-
able information.
Potential weaknesses of the present cohort within the 
context of prognostication of patients with stable coro-
nary heart disease as here defined include the lack of 
information about left ventricle function, body mass 
index and blood pressure, as well as the effects of changes 
in medications during follow-up. Information about post-
infarction heart failure and postinfarction angina pectoris 
was not available to us. But information about the medi-
cation at entry into CLARICOR served as proxy informa-
tion. The lack of left ventricular ejection fraction may be 
partially or completely compensated, as Solomon et al26 
found that age, sex, hypertension, prior acute myocardial 
infarction, creatinine, diuretics and digoxin were related 
to left ventricular ejection fraction, all quantities that we 
have included within the group referred to as ‘standard 
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predictors’. The shortcomings of our data files are miti-
gated by the fact that by design the present study focuses 
on the situation where patients with stable coronary heart 
disease visit a physician for reasons unrelated to the coro-
nary heart disease. Here it might be of value if simple 
clinical information readily available could be used to 
screen these patients with stable coronary heart disease 
to identify high-risk patients who might be referred to a 
more thorough cardiologic examination and follow-up.
It was our hope that the simple ‘standard predictors’ of 
table 1 might serve this purpose, but they proved too little 
informative. Behind this disappointing feature lie undoubt-
edly a meshwork of behavioural and statistical interconnec-
tions that are impossible to unravel. A reviewer has pointed 
out that ‘index event’ phenomena27–29 may also be involved. 
Briefly, to develop an index event (say, infarction), those 
with a given low-risk trait tend to have unrecorded high-risk 
traits, and vice versa, so, to the extent that risk traits are 
permanent, high-low follow-up comparisons will be biased 
when based on such patients. While this is true, there is no 
prognostic bias here as the index event is part of the defini-
tion of the population of interest.
Furthermore, patients, if any, who became eligible for 
the CLARICOR trial during the period 1993–1999 and 
then died before August 1999, are absent. Thus, our data 
do not represent patients as they enter a stable disease state 
(as delimited by CLARICOR exclusion criteria); instead, 
they may be regarded as community patients (subject to 
some self-selection) seen by their physician on a random 
date during their stable state.
Our model was tested using the same data that were 
used to derive it. Therefore, we do not feel it is advisable 
to use the results for predictive purposes without using 
some independent data to calibrate the model, and for 
this and the above-mentioned reasons we have elected 
not to present an explicit prediction model.
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